Loading clinical trials...

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

NCT00035035•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pancreas cancer that cannot be removed by surgery OR that has spread to a new site in your body.
•You must have one tumor that can be physically measured or scanned by the doctor.
•You have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for pancreas cancer, including 5-FU.
•You cannot have any radiation for 4 weeks before starting this study, and you cannot have radiation to the whole pelvis.

Exclusion Criteria

•Treatment with any medication or device that has not been approved by regulatory agencies, like the FDA, at the time you enter the study.
•Documentation that the cancer has spread to your brain.
•Pregnant or breastfeeding.
•A second primary cancer.
•Unable to stop aspirin or non-steroidal anti-inflammatory agents (like ibuprofen) for 5-8 days.

Locations (114)

Huntsville, Alabama, United States

Fountain Valley, California, United States

Fullerton, California, United States

Lancaster, California, United States

Los Angeles, California, United States

Pomona, California, United States

Santa Rosa, California, United States

Torrance, California, United States

Fort Collins, Colorado, United States

Hartford, Connecticut, United States

Key Dates

Last Updated

July 19, 2006

Conditions

Pancreatic NeoplasmsMetastases, Neoplasm

Interventions

GEMZAR

DRUG

ALIMTA

DRUG

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697

MesotheliomaNeoplasms+6 more

View study

RECRUITING

Preoperative EUS Elastography for Pancreatic Texture and POPF Prediction After PD

NCT07139236

Pancreatic NeoplasmsPancreatic Fistula

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 19, 2006Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Inclusion Criteria

Exclusion Criteria

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Preoperative EUS Elastography for Pancreatic Texture and POPF Prediction After PD

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer